Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The Company granted stock options to purchase up to an aggregate of
31,000 shares of
About
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. In preclinical studies, MPPs increased drug delivery into ocular tissues more than three-fold by facilitating penetration through the tear film mucus. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181123005036/en/
Source:
For Kala Pharmaceuticals, Inc.
Investors
Michael Schaffzin,
212-362-1200
michael@sternir.com
or
Media
Kari
Watson, 781-235-3060
kwatson@macbiocom.com